Physician profile
David S Korman
NPI 1245297555
$19,864.97
in general payments reported to CMS, 2019-2025
51 companies · $2,707 in 2025
The $2,707 reported for 2025 was more than what 75% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,055 · 2020: $2,350 · 2021: $3,076 · 2022: $3,228 · 2023: $2,876 · 2024: $2,574 · 2025: $2,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,080 · Education: $76.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,080.13 |
| Education | $76.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,152.23 | 2019-2025 | Enbrel, Evenity, Otezla |
| Ucb, INC. | $1,885.85 | 2019-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $1,847.70 | 2019-2025 | |
| Pfizer INC. | $1,420.98 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,355.96 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,064.99 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $926.81 | 2021-2025 | Saphnelo, Flumist Quadrivalent |
| E.R. Squibb & Sons, L.L.C. | $722.29 | 2019-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $712.16 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $675.76 | 2019-2025 | Tremfya |
| Alexion Pharmaceuticals, INC. | $651.88 | 2019-2025 | Strensiq, Ultomiris |
| Lilly USA, LLC | $562.26 | 2019-2025 | Taltz |
| Genentech USA, INC. | $548.77 | 2019-2025 | Actemra, Rituxan, Gazyva |
| Sobi, INC | $498.32 | 2019-2025 | |
| Horizon Therapeutics Plc | $367.93 | 2019-2023 | Krystexxa |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Korman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.